{"classes":[{"categories":[{"measurements":[{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \\>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \\>=50% reduction is presented along with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Number of Participants With PSA50 Response Rate-Part 1 BID","type":"PRIMARY","unitOfMeasure":"Participants"}